Fox Run Management’s Akero Therapeutics AKRO Stock Holding History

Fox Run Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-6,536	Closed	-$310K	–	876
2025 Q3	$310K	Buy	+6,536	New	+$316K	0.05%	667
2025 Q2	–	Sell	-15,848	Closed	-$642K	–	830
2025 Q1	$642K	Buy	+15,848	New	+$672K	0.1%	384
2024 Q2	–	Sell	-12,823	Closed	-$324K	–	754
2024 Q1	$324K	Buy	+12,823	New	+$308K	0.07%	515
2023 Q2	–	Sell	-7,924	Closed	-$303K	–	659
2023 Q1	$303K	Buy	+7,924	New	+$353K	0.1%	399

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Fox Run Management's AKRO Position: Q4 2025 in Review

Fox Run Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 6,536 shares — an estimated $310K sold.

Fox Run Management first reported a position in AKRO in Q1 2023 and held it in 4 quarters. The position peaked at $642K in Q1 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Fox Run Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Fox Run Management sold 6,536 Akero Therapeutics shares in Q4 2025, an estimated $310K.
Fox Run Management first reported a position in Akero Therapeutics in Q1 2023 and held it in 4 quarters.
Fox Run Management's Akero Therapeutics position peaked at $642K in Q1 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Fox Run Management's 13F filing for Q4 2025, filed 11 Feb 2026.